All studies
RecruitingHuman Pharmacology (Phase I)- First administration to humansInterventional

Live Attenuated Rift Valley Fever Vaccine for Single Shot Administration (LARISSA)

The LARISSA clinical trial is an early-stage study testing a new vaccine designed to prevent Rift Valley fever. Rift Valley fever is a viral illness spread mainly by mosquito bites and contact with infected animals. While it mostly occurs in parts of Africa and the Middle East, it can cause severe disease, and there is currently no widely available human vaccine. This trial is a Phase 1 study, meaning it is the first time this specific vaccine is being given to people. The vaccine is 'live attenuated', which means it uses a weakened version of the virus to teach the immune system how to fight it off. Researchers want to see if a single injection is safe, well-tolerated, and able to trigger an immune response in healthy adults aged 18 and over. Taking part involves health checks, a single vaccine dose, and follow-up visits.

At a glance

Status
Recruiting
Phase
Human Pharmacology (Phase I)- First administration to humans
Sponsor
Cr2o B.V.
Enrolment target
75
Start
26 Jul 2022

What is this study about?

Rift Valley fever is a viral infection that affects both animals and humans. It is mainly spread by mosquito bites or through direct contact with blood or body fluids from infected livestock. For many people, it causes mild flu-like symptoms, such as fever, muscle aches, and headaches. However, in some cases, it can lead to serious complications, including severe eye damage, brain inflammation, or internal bleeding. Currently, there are limited treatment options and no widely licensed human vaccines.

The LARISSA study aims to change this by testing a new preventative vaccine. This vaccine is designed to work with just one injection. It is a 'live attenuated' vaccine, which means it contains a very weak form of the Rift Valley fever virus. This weakened virus cannot cause severe illness in healthy people, but it is strong enough to train your immune system so your body can recognise and fight off the real infection in the future.

Because this is a Phase 1 trial, it represents the first time this vaccine is being tested in humans. The main goal is not yet to prove that it stops infection in daily life, but rather to check its safety, see what side effects occur, and measure how the human immune system reacts to it. The results will help scientists decide if the vaccine can move forward into larger clinical trials.

Key takeaways

  • LARISSA is testing a new single-dose vaccine against Rift Valley fever in humans for the first time.
  • The main purpose of the study is to evaluate safety and check how the immune system responds.
  • The study is open to adults aged 18 and older who meet the health criteria.
  • Volunteers receive one injection followed by regular clinic check-ups and blood tests.
  • Participation is entirely voluntary, and you can leave the study at any time.

Who may be eligible?

The LARISSA trial is open to adults aged 18 and older. Because this is an early safety trial, researchers are generally looking for healthy volunteers whose bodies can mount a normal immune response without extra health risks.

You might not be able to join if you have certain long-term health conditions, particularly conditions that weaken your immune system, or if you take medications that affect how your immune system works. This is an important safety precaution because the vaccine uses a weakened live virus.

Pregnant or breastfeeding women are typically not eligible to join first-in-human vaccine trials to ensure the safety of both mother and baby. The study team will run full health checks and blood tests to confirm whether taking part is safe for you.

Could this study suit you?

Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.

  1. I am aged 18 or older.
  2. I am generally in good overall health.
  3. I do not have a condition that weakens my immune system.
  4. I am not currently pregnant or breastfeeding.
  5. I am willing to attend regular follow-up visits and have routine blood tests.
Answer every question to see your result.

What does participation involve?

If you decide to take part, you will first attend a screening visit where the trial team explains the study, answers your questions, and carries out basic health checks like blood tests and blood pressure measurements. If you are eligible, you will receive a single injection of the vaccine into your muscle, usually in the upper arm. After the injection, you will stay at the clinic for a short period so doctors can monitor you for any immediate reactions. Over the following weeks and months, you will attend several follow-up clinic visits so the team can check your health, ask about any symptoms, and take blood samples to measure your immune response. The total study duration usually lasts between six months and a year.

Potential risks and benefits

Taking part in this study may not offer any direct health benefit to you, as researchers do not yet know if the vaccine provides strong protection against Rift Valley fever. However, your participation could help develop a vital vaccine that protects vulnerable communities and travellers in the future. As with any vaccine, you may experience mild side effects such as soreness, redness, or swelling where you had the injection, or temporary flu-like symptoms like a low fever, headache, or tiredness. Because this is a first-in-human study, unforeseen side effects are possible. Your safety is monitored closely throughout, and you are free to leave the trial at any time without giving a reason and without your normal medical care being affected.

Locations (1)

Some site locations are approximate. We're improving this — please verify with the trial team before travelling.
  • —
    Unverified
    Belgium

Common questions

What is Rift Valley fever?

It is a viral disease spread by mosquitoes and contact with infected animals, found mainly in Africa and the Arabian Peninsula, which can cause fever and occasionally severe health problems.

What does 'live attenuated' mean?

It means the vaccine uses a weakened version of the natural virus. It is strong enough to teach your immune system how to defend itself, but too weak to cause severe illness in healthy people.

Will taking part guarantee I am protected from the virus?

No. Because this is an early safety trial, doctors are still discovering how effective the vaccine is, so you cannot assume you are fully immune.

What is a Phase 1 clinical trial?

A Phase 1 trial is the earliest stage of human testing. It focuses mainly on finding out whether a new treatment is safe and what side effects it might cause.

Can I leave the study if I change my mind?

Yes. Taking part is completely voluntary, and you can withdraw from the study at any point without it affecting your standard medical care.

How to find out more

Always speak to your GP or specialist before deciding to take part in a study.

Interested in taking part?

Register your interest

Share your details and the research team for "Live Attenuated Rift Valley Fever Vaccine for Single Shot Ad…" will contact you if you may be eligible. Always speak to your GP before agreeing to take part.

Discussion

Community discussion

Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.